Lyell Immunopharma, Inc. LYEL
We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with cancer. Our goal is to fully realize the curative potential of cell therapy for patients with hematologic malignancies and solid tumors. To achieve this, we are pioneering novel approaches designed to generate T‑cell therapies that drive long-lasting clinical responses. Our CAR T-cell product candidates start with the identification of promising cancer targets. We then engineer the patient's own living immune cells and arm them with our innovative enhancements, including CAR constructs, technologies and manufacturing protocols that are designed to endow T cells with more potent cancer cell killing capabilities.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.7M | $10.7M | $7.8M | $657.0K | — |
| R&D | — | — | $182.9M | $159.2M | $138.7M | $182.2M | $63.6M | — |
| SG&A | $45.1M | $52.0M | $67.0M | $117.3M | $89.1M | $46.9M | $39.2M | — |
| Total operating expenses | $269.4M | $358.8M | $247.1M | $271.7M | $225.4M | $219.7M | $102.7M | — |
| Operating income | -$269.4M | -$358.8M | -$247.0M | -$187.1M | -$214.8M | -$211.9M | -$102.1M | — |
| Pre-tax income | -$274.4M | — | — | — | — | — | — | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$274.4M | -$343.0M | -$234.6M | -$183.1M | -$250.2M | -$204.5M | -$129.4M | — |
| EPS, basic | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 | — |
| EPS, diluted | -16.06 | -26.23 | -18.70 | -0.74 | -1.84 | -15.69 | -24.04 | — |
| Shares, diluted (wtd. avg.) | $17.1M | $13.1M | $12.5M | $247.1M | $135.9M | $13.3M | $5.4K | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $60.2M | $105.6M | $145.6M | $123.8M | $294.3M | $140.9M | $98.5M | $130.3M |
| Short-term investments | $187.0M | $264.9M | $400.6M | $516.6M | $321.0M | $472.2M | — | — |
| Total current assets | $260.9M | $379.6M | $554.7M | $651.3M | $626.3M | $617.5M | — | — |
| Property, plant and equipment | $34.8M | $48.2M | $102.7M | $123.0M | $120.1M | $77.0M | — | — |
| Total assets | $340.1M | $490.9M | $750.0M | $937.6M | $1.13B | $908.3M | — | — |
| Accounts payable | $2.9M | $5.4M | $4.8M | $3.9M | $3.2M | $9.4M | — | — |
| Total current liabilities | $49.4M | $53.8M | $34.5M | $37.0M | $46.7M | $49.3M | — | — |
| Total liabilities | $91.8M | $108.0M | $95.1M | $104.3M | $197.6M | $189.8M | — | — |
| Retained earnings | -$1.62B | -$1.35B | -$1.00B | -$767.5M | -$584.4M | -$334.1M | — | — |
| Total equity | $248.2M | $382.8M | $655.0M | $833.3M | $929.8M | -$292.5M | -$111.1M | $850.0K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$150.0M | -$162.4M | -$163.7M | -$169.6M | -$126.2M | -$160.9M | $39.5M | — |
| Depreciation and amortisation | $11.5M | $19.6M | $20.2M | $18.0M | $13.6M | $4.3M | $1.3M | — |
| Stock-based compensation | $41.8M | $33.1M | $47.1M | $81.9M | $62.2M | $33.3M | $15.7M | — |
| Capital expenditure | $780.0K | $464.0K | $2.7M | $24.3M | $65.5M | $51.5M | $16.0M | — |
| Investing cash flow | $54.1M | $122.4M | $184.0M | -$11.5M | -$121.6M | -$273.5M | -$422.4M | — |
| Financing cash flow | $50.4M | $1.3M | $1.7M | $10.6M | $401.2M | $476.8M | $351.2M | — |
| Buybacks | — | — | — | $0 | $0 | $11.8M | $185.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016686.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |